Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;157(3):219-231.
doi: 10.1111/imm.13064. Epub 2019 May 22.

Regulation of regulatory T cells in cancer

Affiliations
Review

Regulation of regulatory T cells in cancer

Julie Stockis et al. Immunology. 2019 Jul.

Abstract

The inflammatory response to transformed cells forms the cornerstone of natural or therapeutically induced protective immunity to cancer. Regulatory T (Treg) cells are known for their critical role in suppressing inflammation, and therefore can antagonize effective anti-cancer immune responses. As such, Treg cells can play detrimental roles in tumour progression and in the response to both conventional and immune-based cancer therapies. Recent advances in our understanding of Treg cells reveal complex niche-specific regulatory programmes and functions, which are likely to extrapolate to cancer. The regulation of Treg cells is reliant on upstream cues from haematopoietic and non-immune cells, which dictates their genetic, epigenetic and downstream functional programmes. In this review we will discuss how Treg cells are themselves regulated in normal and transformed tissues, and the implications of this cross talk on tumour growth.

Keywords: cancer; chemokine/chemokine receptors; cytokines/cytokine receptors; regulatory T cells; tumour immunology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Origin of regulatory T (Treg) cells in tumours. Depicted are the three scenarios – not mutually exclusive – that could account for the presence of Treg cells within tumours. Left, conversion of naive CD4+ T cells into peripheral Treg (pTreg) cells; centre, recruitment of thymus‐derived Treg (tTreg) cells from the circulation; right, expansion of tissue‐resident Treg cells.
Figure 2
Figure 2
Co‐stimulatory, co‐inhibitory and cytokine receptors expressed by regulatory T (Treg) cells in tumours. Co‐stimulatory (left) and co‐inhibitory (middle) molecules, as well as cytokine receptors (right), deliver signals to Treg cells following engagement by their ligands expressed by immune and/or non‐immune cell types within the tumour. Positive and negative signs in the Treg cell indicate either a positive effect on proliferation (Prolif.) or function (Funct.) or an inhibitory effect (i.e. reduced function), respectively, after receptor engagement. Question marks (?) indicate that the outcome of the receptor engagement in the Treg cell warrants further investigation.

Similar articles

Cited by

References

    1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883–99. - PMC - PubMed
    1. Fridman WH, Pages F, Sautes‐Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298–306. - PubMed
    1. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523–32. - PMC - PubMed
    1. Shevach EM. Mechanisms of foxp3+ T regulatory cell‐mediated suppression. Immunity 2009; 30:636–45. - PubMed
    1. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531–64. - PMC - PubMed

Publication types

Substances